{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of a Novel Surgeon-Placed Adductor Canal Block in Total Knee Arthroplasty"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to receive either the novel ACB technique or a standard single-shot ACB by anesthesia."
      },
      "Participants": {
        "score": 2,
        "evidence": "56 consecutive patients undergoing primary TKA by a single surgeon."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either the novel ACB technique or a standard single-shot ACB by anesthesia."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates a novel surgeon-placed adductor canal block (ACB) with catheter placement for continuous regional nerve block, aiming to reduce pain and opioid use post-TKA."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was perioperative pain measured by a visual analog scale (VAS) over seven days postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was achieved through consecutive patient presentation."
      },
      "Blinding": {
        "score": 0,
        "evidence": "no blinding of patients or clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted between July and November 2017, involving 56 consecutive patients."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Forty-eight patients initiated the survey, and 36 completed it."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The novel ACB group showed a 25% reduction in VAS pain scores (3.9 to 2.9), a 24% reduction in opioid use, and significant reductions in side effects compared to the control group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported in the novel ACB group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 16,
    "max_score": 25
  },
  "model": "gpt-4o"
}